Clostridium Difficile infections Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

By Company 1.2.2. Analysis by Phase 1.2.3. By Molecule Type 1.2.4. By region 2. Disease Overview 2.1.1. Introduction 2.1.2. Classification 2.1.3. Symptoms 2.1.4. Causes 2.1.5. Diagnoses 2.1.6. Treatment 2.1.7. Epidemiology 3. Executive Summary 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunities 5. Pipeline Analysis/Outlook 5.1. Analysis by Company 5.2. Analysis by Phase 5.2.1. Phase of Development 5.2.1.1. Introduction 5.2.1.1.1. Drug Profiling • Drug Name • Generic Name • Synonyms • Company • Collaborator • Route of administration • Target • Mechanism of Action • Technology • Molecule type • CAS Number • Weight • Chemical Formula • IUPAC name • ATC code 5.2.1.1.2. Strategic Developments 5.2.1.1.3. Clinical trials 5.2.1.1.4. Clinical trial results 5.2.1.1.5. Patents 5.2.1.1.6. Technology 5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph) 5.3. By Molecule type 5.4. Analysis by Region 6. Company profiling 6.1. Absynth Biologics 6.1.1. Introduction 6.1.2. Financials 6.1.3. Products and Services 6.1.4. SWOT 6.2. XBiotech 6.2.1. Introduction 6.2.2. Financials 6.2.3. Products and Services 6.2.4. SWOT 6.3. Vitality Biopharma 6.3.1. Introduction 6.3.2. Financials 6.3.3. Products and Services 6.3.4. SWOT 6.4. Valneva SE 6.4.1. Introduction 6.4.2. Financials 6.4.3. Products and Services 6.4.4. SWOT 6.5. Valevia 6.5.1. Introduction 6.5.2. Financials 6.5.3. Products and Services 6.5.4. SWOT 6.6. Astellas Pharma Inc. 6.6.1. Introduction 6.6.2. Financials 6.6.3. Products and Services 6.6.4. SWOT 6.7. Seres Therapeutics 6.7.1. Introduction 6.7.2. Financials 6.7.3. Products and Services 6.7.4. SWOT 6.8. Summit Therapeutics plc 6.8.1. Introduction 6.8.2. Financials 6.8.3. Products and Services 6.8.4. SWOT 6.9. Otsuka Holdings Co., Ltd. 6.9.1. Introduction 6.9.2. Financials 6.9.3. Products and Services 6.9.4. SWOT 6.10. Immuron 6.10.1. Introduction 6.10.2. Financials 6.10.3. Products and Services 6.10.4. SWOT 6.11. Actelion Pharmaceuticals Ltd 6.12.1. Introduction 6.12.1. Financials 6.12.2. Products and Services 6.12.3. SWOT 6.13. Novartis AG 6.13.1. Introduction 6.13.1. Financials 6.13.2. Products and Services 6.13.3. SWOT 6.14. Sanofi 6.14.1. Introduction 6.14.2. Financials 6.14.3. Products and Services 6.14.4. SWOT 6.15. Synthetic Biologics, Inc. 6.15.1. Introduction 6.15.2. Financials 6.15.3. Products and Services 6.15.4. SWOT 6.16. ImmuneBiotech AB 6.16.1. Introduction 6.16.2. Financials 6.16.3. Products and Services 6.16.4. SWOT 6.17. Finch Therapeutics Group 6.17.1. Introduction 6.17.2. Financials 6.17.3. Products and Services 6.17.4. SWOT 6.18. PROKARIUM 6.18.1. Introduction 6.18.2. Financials 6.18.3. Products and Services 6.18.4. SWOT 6.19. C3J Therapeutics 6.19.1. Introduction 6.19.2. Financials 6.19.3. Products and Services 6.19.4. SWOT 6.20. Crestone Inc. 6.20.1. Introduction 6.20.2. Financials 6.20.3. Products and Services